trending Market Intelligence /marketintelligence/en/news-insights/trending/iaawoutp9-vy6rbp82f6pw2 content esgSubNav
In This List

Mylan's generic version of Pfizer birth control injection wins US FDA approval

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Mylan's generic version of Pfizer birth control injection wins US FDA approval

The U.S. Food and Drug Administration approved Mylan NV's generic version of Pfizer Inc.'s birth control injection Depo-Provera.

Mylan is offering the hormonal contraceptive medroxyprogesterone acetate in single-dose vials.

Sales of the drug in the U.S. were about $181 million for the year ending July 31, the company said in an Oct. 18 news release, citing IQVIA data.

Mylan develops and markets generic, brand-name and over-the-counter products worldwide.